Prognostic scores for predicting overall survival in patients with metastatic renal and urothelial cancer undergoing immunotherapy - which one to use?

1

Immunotherapy is now standard for treating metastatic renal cell carcinoma and urothelial carcinoma, improving patient outcomes.
2

Prognostic scores like NLR, SII, NER, and mGPS are being evaluated to predict overall survival in patients undergoing immunotherapy.
3

High neutrophil-to-lymphocyte ratio and systemic immune-inflammation index correlate with worse progression-free and overall survival.
4

The study analyzed 120 patients, revealing significant differences in demographics and prior therapies between mUC and mRCC patients.
5

No universally accepted risk score exists for metastatic urological cancers, highlighting the need for reliable prognostic tools.

World Journal Of Urology

by Margarete Teresa Walach, Ralph Burger, Felix Brumm, Katja Nitschke, Frederik Wessels, Philipp Nuhn, Thomas Stephan Worst, Jost von Hardenberg, Britta Grüne, Jonas Jarczyk
January 29, 2025

1